|Day Low/High||14.86 / 15.86|
|52 Wk Low/High||11.55 / 24.99|
Let's look at the charts and indicators to come up with a formula for success.
The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.
The key to dealing with this environment is to keep an open mind.
VenBio gained four seats on Immunomedics' board of directors.
The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.
Immunomedics has been for sale for quite some time, but there hasn't been any interest in it. Here's why.